This article was originally published in The Tan Sheet
Pharmaceutical Formulations first quarter net sales reached $18.4 mil., a 13.2% increase over the comparable period last year, attributable to the addition of sales from Konsyl Pharmaceuticals, acquired roughly one year ago. Excluding Konsyl, sales fell 2.2% to $15.9 mil., reflecting "increased price competition in the private label over-the-counter market, higher retailer rebate programs and an abrupt decline in the overall cough/cold market in the first quarter 2004." Edison, N.J. firm incurred a net loss of $1.4 mil in the quarter, compared to a $548,000 deficit the prior year, due to lower private label sales and higher selling, general and administrative expenses, company says...
You may also be interested in...
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.